TY - JOUR T1 - Time Trends in Opioid Use Disorder Hospitalizations in Gout, Rheumatoid Arthritis, Fibromyalgia, Osteoarthritis, and Low Back Pain JF - The Journal of Rheumatology JO - J Rheumatol SP - 775 LP - 784 DO - 10.3899/jrheum.191370 VL - 48 IS - 5 AU - Jasvinder A. Singh AU - John D. Cleveland Y1 - 2021/05/01 UR - http://www.jrheum.org/content/48/5/775.abstract N2 - Objective To examine opioid use disorder (OUD)–related hospitalizations and associated healthcare utilization outcomes in people with 5 common musculoskeletal diseases (MSD).Methods We used the US National Inpatient Sample (NIS) data from 1998 to 2014 to examine the rates of OUD hospitalizations (per 100,000 NIS claims overall), time trends, and outcomes in 5 common rheumatic diseases: gout, rheumatoid arthritis (RA), fibromyalgia (FM), osteoarthritis (OA), and low back pain (LBP).Results OUD hospitalization rate per 100,000 total NIS claims in 1998–2000 vs 2015–2016 (and increase) were as follows: gout, 0.05 vs 1.88 (36-fold); OA, 0.68 vs 10.22 (14-fold); FM, 0.53 vs 6.98 (12-fold); RA, 0.30 vs 3.16 (9.5-fold); and LBP, 1.17 vs 7.64 (5.5-fold). The median hospital charges and hospital stays for OUD hospitalizations were as follows: gout, $18,363 and 2.5 days; RA, $17,398 and 2.4 days; FM, $15,772 and 2.1 days; OA, $16,795 and 2.4 days; and LBP, $13,722 and 2.0 days. In-hospital mortality rates ranged from 0.9% for LBP and FM to 1.7% for gout with OUD hospitalizations. Compared to those without each MSD, age-, sex-, race-, and income-adjusted total hospital charges (inflation-adjusted) for OUD hospitalizations with each rheumatic disease were as follows: gout, $697 higher; OA, $4759 lower; FM, $2082 lower; RA, $1258 lower; and LBP, $4944 lower.Conclusion OUD hospitalizations increased in all 5 MSD studied, but the rate of increase differed. Awareness of these OUD hospitalization trends in 5 MSD among providers, policy makers, and patients is important. Development and implementation of interventions, policies, and practices to potentially reduce OUD-associated effects in people with rheumatic diseases is needed. ER -